The activities during the European Immunisation Week demonstrate a common momentum by member states of the World Health Organization (WHO) European Region to increase the success of immunisation programmes through advocacy and targeted communication. These efforts ultimately aim to raise awareness and reach people who have not been immunised or did not receive all recommended vaccinations. Fifty-two countries agreed to participate in 2011, the largest number since the first European Immunisation Week in 2005 [1]. This proves increasing political commitment to vaccination throughout the region. It's thus a good time to celebrate advances in vaccination programmes as the first decade of the 21st century has been the most productive in the history of vaccine development. New life-saving and disease-preventing vaccines, such as conjugate vaccines against pneumococcal and meningococcal disease, human papilloma virus (HPV) and second-generation rotavirus vaccines have been developed, and others will soon be available.

These exciting advances, however, must not hide some major challenges of vaccination programmes in the European Region. The first one is illustrated by the failure of reaching the European measles elimination goal by 2010 [2]. In early 2011, thirty countries in the region have reported a marked increase in measles cases, with over 6,500 cases as of 20 April 2011 [1]. This demonstrates the difficulty in reaching in our societies the required high proportion of immune subjects, including the 95% coverage of those targeted for vaccination with two doses of a measles-containing vaccine, as a result of several problems. Firstly there is a growing paradigm where people feel more than in the past responsible for their own health. They wish to choose their own medical care in a context where vaccination, rumours and other misconceptions, well-targeted information and social mobilisation campaigns are required to transform passive acceptance of immunisation into a well-informed demand for vaccines that can protect against life-threatening diseases [5]. Such a transformation requires investment in form of human and financial resources and a strong commitment from health authorities. This is sometimes lacking. Again, using measles prevention as an example, the investment (time, energy, money, identification of innovative communication or vaccine delivery strategies and the staff to do it) required to gain the few per cent of coverage needed to reach the herd immunity threshold through reaching those underserved or reluctant, is considered in many countries as not worth the investment. The challenge is to convince decision makers that 90% coverage in children is unsatisfactory and that even 1% of the number of measles cases that occurred in the pre-vaccination era must now be considered a public health emergency! European failure to meet measles elimination means we must increase investment in supplementary and outreach vaccination activities to ensure we reach also underserved...
and marginalised groups. In addition those older children and young people who are vulnerable due to sub-optimal immunisation coverage in the past should be offered catch-up opportunities to complete the recommended schedules. Failure to do so will leave Europeans susceptible to importations of measles as illustrated in the communication from Brown et al. in this issue describing the recent appearance of a novel measles G3 strain in multiple European countries [6]. Furthermore, Wicker et al. highlight in their paper that also healthcare workers need to be educated and convinced about the necessity to protect themselves and their patients through for example influenza vaccination [7]. Previous papers in this journal have demonstrated the same for the measles, mumps, rubella vaccine [8-10].

The second challenge is the growing gap in the number of vaccinations offered by the various European countries as new vaccines are marketed. These new vaccines are generally much more expensive than those that have been used for a long time. In the context of growing financial constraints, cost becomes a major impediment in integrating these new vaccines. The example of vaccination against HPV is illustrative of this situation, as shown by the results of the Venice surveys [11,12]. The financial barrier is documented in those surveys by the answers to the question: ‘Why did you not introduce the HPV vaccination?’ for which the main reason was: ‘because of the cost of the vaccine or cost/effectiveness issue’.

The recent financial challenges threaten to unravel hard-won gains particularly in countries hardest hit by the economic turmoil. Many countries are now facing down-sizing of staff working in public health services. With an emphasis on protecting front-line services, vaccine programme functions such as collection of data on vaccine preventable diseases and monitoring vaccine coverage may be threatened. Effective surveillance systems are indispensable in guiding policy decisions for the introduction of new vaccines, monitoring their impact on disease incidence, and conducting post-marketing surveillance to ensure their safety.

It is also essential that we continue to ensure that all vaccines in our programmes continue to be reviewed and where no longer indicated discontinued after careful evaluation. Such a review has recently led the United Kingdom Joint Committee on Vaccination and Immunisation to consider cessation of the elderly pneumococcal polysaccharide vaccine programme [13]. In recent years countries such as France and Finland have discontinued routine universal BCG programmes [14,15].

On a more positive note, these recessionary times may be the impetus needed to review the process whereby European countries procure vaccine. In many countries vaccine procurement is devolved to local levels, losing the economies of scale that national procurement of vaccines can provide. We could learn from the experience of other WHO Regions such as provided by the Pan American Health Organization (PAHO). In 1979, PAHO established a revolving fund to help all countries in the region become more self-sufficient in the purchase of vaccines for routine immunisation [5]. The pooled fund is able to secure low vaccine prices through large volume contracts with manufacturers.

As the current economic downturn unfolds, it will be important for governments to sustain and, when possible, increase investments in immunisation. Comparison of vaccination programmes with other healthcare interventions indicates that vaccines are often one of society’s best healthcare investments [16]. We, public health experts, need to ensure that we provide policy makers with the evidence to justify their investment decisions and ensure that our vaccination programmes are recession proof.

References


